Applying Japanese pharmacopeia draft purity test methods to atrovastatin calcium hydrate impurity profiling using 2D-LCMS-IT-TOF system

Importance of the Topic

Pharmaceutical companies face growing pressure to characterize trace impurities as patent expirations invite generic competition. Regulatory bodies such as the Japanese Pharmacopeia impose stringent purity requirements on active pharmaceutical ingredients, and advanced analytical workflows are needed to ensure compliance and product safety.

Objectives and Study Overview

This study demonstrates the application of draft Japanese Pharmacopeia purity test procedures to impurity profiling of atorvastatin calcium hydrate using an automated two-dimensional LCMS-IT-TOF system. It aims to detect, separate, and identify impurities present at low levels in the API.

Methodology and Instrumentation

Sample preparation involved a 1000 µg/mL solution of atorvastatin calcium hydrate in water/acetonitrile (1:1). A comprehensive two-dimensional separation was performed:

• First-dimension HPLC: Shim-pack VP-ODS column with citrate buffer (pH 5.0) and acetonitrile/tetrahydrofuran mobile phases, UV detection at 254 nm.
• Second-dimension LCMS: Shim-pack XR-ODS column with acetate buffer (pH 5.0) and acetonitrile gradient, interfaced to an IT-TOF mass spectrometer for high-accuracy mass measurements and MSn fragmentation.

Main Results and Discussion

Using the JP-based HPLC, 19 impurity peaks were observed by UV, with 10 exceeding 0.1% area. Two-dimensional LCMS analysis resolved these into 23 individual components. Impurity 3 (m/z 717) was identified as European Pharmacopeia Impurity F by accurate mass and MSn fragmentation. A low-level impurity at 0.013% (Impurity 2) yielded clear mass spectra, demonstrating high sensitivity. Impurity 6 comprised two co-eluting substances (m/z 541 and 557), confirmed by precise fraction collection and mass analysis.

Benefits and Practical Applications

• The 2D-LCMS-IT-TOF arrangement combines high chromatographic resolution with accurate mass measurement, enabling detection of minor impurities.
• MSn data facilitate structural elucidation, supporting identity confirmation against pharmacopeial standards.
• The automated system streamlines compliance testing for generic drug development and quality control workflows.

Future Trends and Opportunities

• Integration of advanced software for automated peak annotation and data processing.
• Expansion to three-dimensional separations and coupling with complementary detectors.
• Application of artificial intelligence and machine learning for impurity prediction and identification.
• Use of high-resolution mass spectrometry to further enhance detection limits and compound characterization.

Conclusion

The implementation of Japanese Pharmacopeia draft methods on a 2D-LCMS-IT-TOF platform successfully profiled atorvastatin impurities, achieving sensitive detection, separation of co-eluting species, and unambiguous structural confirmation. This workflow offers a robust solution for regulatory compliance and in-depth impurity assessment in pharmaceutical development.

Reference

1. Ogura T, Hirano I, Inohana Y, Hayakawa Y, Nakai T. Applying Japanese Pharmacopeia draft purity test methods to atorvastatin calcium hydrate impurity profiling using 2D-LCMS-IT-TOF system. ASMS 2011 MP08; Shimadzu Corporation, Kyoto, Japan.